Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Growth: High-optionality pipeline in obesity offers massive upside not currently priced in.
Contrarian: The market's -0.48% growth assumption is overly pessimistic and ignores structural cash power.
Amgen Inc. is a premier Mature Compounder generating $13.4B in annual FCFF with a 101% ROE. The market currently prices in a perpetual growth decline of -0.48%, reflecting deep skepticism over patent cliffs. Our analysis suggests this ignores the durable cash generation from legacy assets and significant upside optionality in the obesity pipeline (MariTide).
Amgen Inc. is a premier Mature Compounder generating $13.4B in annual FCFF with a 101% ROE. The market currently prices in a perpetual growth decline of -0.48%, reflecting deep skepticism over patent cliffs. Our analysis suggests this ignores the durable cash generation from legacy assets and significant upside optionality in the obesity pipeline (MariTide).
Extensive patent portfolio and regulatory exclusivity
Manufacturing scale and complexity in biologics
Contrarian: The market's -0.48% growth assumption is overly pessimistic and ignores structural cash power.
Strong Buy. Capitalize on the irrational discount applied to a dominant cash compounder.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
A bear case scenario assumes a 20% margin compression and 5% annual revenue decline. This resets the fair value to the $366 level, providing a margin of safety near current market prices.
Extensive patent portfolio and regulatory exclusivity
Manufacturing scale and complexity in biologics
High physician/patient switching costs for chronic therapies
Robust R&D platform and pipeline integration
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $13.4B after capex $1.8B, with terminal value at 75.4% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
Prioritize MariTide data readouts as the primary sentiment driver. If data is positive, look for revenue re-acceleration. If negative, focus on debt repayment and dividend coverage.
Prioritize MariTide data readouts as the primary sentiment driver. If data is positive, look for revenue re-acceleration. If negative, focus on debt repayment and dividend coverage.
Prioritize MariTide data readouts as the primary sentiment driver. If data is positive, look for revenue re-acceleration. If negative, focus on debt repayment and dividend coverage.
Amgen is in a strategic reinvestment phase, utilizing legacy cash flows to fund high-cost R&D and large-scale M&A to replace expiring patent revenues.
Accelerated adoption of GLP-1/GIP obesity therapies and successful oncology R&D breakthroughs.
Regulatory pricing headwinds in the US and patent loss-of-exclusivity (LOE) concentration.
Amgen is in a strategic reinvestment phase, utilizing legacy cash flows to fund high-cost R&D and large-scale M&A to replace expiring patent revenues.
Appropriate for a core healthcare holding.
Initial trim at $480 (near base fair value); full exit consideration above $580 if pipeline optionality fully prices in.
Contrarian: The market's -0.48% growth assumption is overly pessimistic and ignores structural cash power.
Income/Value: FCF support and dividend yield provide a hard floor during market volatility.
Strong Buy. Amgen is a high-quality cash generator trading at a significant discount to its intrinsic compounding value.
Upside case: Growth: High-optionality pipeline in obesity offers massive upside not currently priced in. Downside case: Contrarian: The market's -0.48% growth assumption is overly pessimistic and ignores structural cash power.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Steeper declines in legacy products and pipeline disappointments lead to valuation anchoring at the FCF yield floor.
Obesity pipeline asset MariTide fails to meet efficacy or safety endpoints in Phase 2/3, removing the primary growth re-acceleration catalyst.
CMS negotiations result in net price reductions exceeding 40% for top assets Enbrel and Prolia, significantly faster than model decay assumptions.
Synergies from the Horizon acquisition fail to materialize while high interest rates increase the burden of the $54.6B debt load, strangling FCF.
The five developments that would weaken our investment case.
Divergence between accounting profits and cash generation signals working capital strain, limiting debt deleveraging capacity and threatening the safety of quarterly capital distributions.
Current:1.291 as of the report's 2026-05-08 analysis date
Alert if< 1.000 over any trailing twelve-month period
Accelerating government pricing concessions on legacy biopharmaceuticals and adverse product mix shifts would compress manufacturing spreads, limiting funding for internal drug development.
Current:67.2% for the period ended 2025-12-31
Alert if< 65.0% over two consecutive fiscal quarters
Pipeline failure in high-conviction metabolic programs diminishes long-term commercial returns, stranding heavy developmental outlays and lowering overall corporate capital productivity.
Current:14.6% as of the report's 2026-05-08 analysis date
Alert if< 10.0% over any rolling twelve-month period
Higher integration expenses and heavy debt service obligations would constrain operating profitability, elevating leverage risks and reducing flexibility for strategic acquisitions.
Current:24.7% for the period ended 2025-12-31
Alert if< 20.0% over any trailing twelve-month period
Decelerating demand across key newly launched commercial therapies fails to offset patent expiries in mature biologics, precipitating total enterprise top-line contraction.
Current:10.0% for the period ended 2025-12-31
Alert if< 0.0% across any fiscal year
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Successful commercialization of the obesity pipeline and oncology breakthroughs drive top-line re-acceleration and multiple expansion.
Amgen successfully navigates patent cliffs via moderate new product growth and asset acquisitions, maintaining its compounder status.
Prioritize MariTide data readouts as the primary sentiment driver. If data is positive, look for revenue re-acceleration. If negative, focus on debt repayment and dividend coverage.
Warning level: < 1.000 over any trailing twelve-month period. Divergence between accounting profits and cash generation signals working capital strain, limiting debt deleveraging capacity and threatening the safety of quarterly capital distributions.
Warning level: < 65.0% over two consecutive fiscal quarters. Accelerating government pricing concessions on legacy biopharmaceuticals and adverse product mix shifts would compress manufacturing spreads, limiting funding for internal drug development.
Warning level: < 10.0% over any rolling twelve-month period. Pipeline failure in high-conviction metabolic programs diminishes long-term commercial returns, stranding heavy developmental outlays and lowering overall corporate capital productivity.
Warning level: < 20.0% over any trailing twelve-month period. Higher integration expenses and heavy debt service obligations would constrain operating profitability, elevating leverage risks and reducing flexibility for strategic acquisitions.
Warning level: < 0.0% across any fiscal year. Decelerating demand across key newly launched commercial therapies fails to offset patent expiries in mature biologics, precipitating total enterprise top-line contraction.
| $28.19B |
| $33.42B |
| $36.75B |
| +11.8% |
| Gross profit | $19.92B | $19.74B | $20.57B | $24.71B | +7.5% |
| Operating income | $8.75B | $10.73B | $7.76B | $11.73B | +10.3% |
| Net income | $6.55B | $6.72B | $4.09B | $7.71B | +5.6% |
| EPS (diluted) | $12.11 | $12.49 | $7.56 | $14.23 | +5.5% |
| EBITDA | $12.17B | $14.80B | $13.36B | $16.90B | +11.6% |
| R&D | $4.43B | $4.78B | $5.96B | $7.27B | +17.9% |
| SG&A | $5.41B | $6.18B | $7.10B | $7.05B | +9.2% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 36,751,000,000 |
|---|---|
| Cost of revenue | 12,037,000,000 |
| Gross profit | 24,714,000,000 |
| Operating expenses | 15,634,000,000 |
| Operating income | 9,080,000,000 |
| Non-operating items and tax | -1,369,000,000 |
| Net income | 7,711,000,000 |
| Total assets | 90,586,000,000 |
|---|---|
| Cash | 9,129,000,000 |
| Current assets | 29,057,000,000 |
| Total liabilities | 81,928,000,000 |
| Current liabilities | 25,489,000,000 |
| Shareholders’ equity | 8,658,000,000 |
Point-in-time financial data used in the 2026-05-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 26.3B | 12.2B | 6.6B | 9.7B | 8.8B | 936M | 3.4B | 401M | 6.4B | 4.2B | 6.9B | — | — | — | — | 7.6B | 38.9B | 36.3% | — | 6.0% | — |
| 2023-12-31 | 28.2B | 14.8B | 6.7B | 8.5B | 7.4B | 1.1B | 4.1B | 431M | 0 | 4.6B | 26.3B | — | — | — | — | 10.9B | 64.6B | 28.0% | — | 5.7% | — |
| 2024-12-31 | 33.4B | 13.4B | 4.1B | 11.5B | 10.4B | 1.1B | 5.6B | 530M | 200M | 4.8B | -3.6B | — | — | — | — | 12B | 60.1B | 21.7% | — | 6.5% | — |
| 2025-12-31 | 36.8B | 16.9B | 7.7B | 10B | 8.1B | 1.9B | 5.2B | 494M | 0 | 5.1B | -5B | — | — | — | — | 9.1B | 54.6B | 24.7% | — | 5.9% | — |
AMGN trades at 14.0x forward earnings against a peer median of 13.9x; EV/EBITDA of 13.2x against a peer median of 14.1x; 6 peers.
| Johnson & Johnson |
| 17.5x |
| 5.6x |
| 16.6x |
| 26.4% |
| 27.4% |
| ABBV | AbbVie Inc. | 12.5x | 5.7x | 14.1x | 62.2% | 31.6% |
| MRK | Merck & Co. Inc. | 11.8x | 4.2x | 10.9x | 18.9% | 38.6% |
| GILD | Gilead Sciences Inc. | 13.9x | 5.7x | 12.5x | 40.7% | 37.4% |
